XML 38 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Schedule of cash and cash equivalents
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in the Company’s condensed consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017 consisted of the following:
 
Nine Months Ended September 30, 2018
 
Nine Months Ended September 30, 2017
 
Beginning of period
 
End of period
 
Beginning of period
 
End of period
 
(in thousands)
Cash and cash equivalents
$
1,665,412

 
$
2,478,302

 
$
1,183,945

 
$
1,384,966

Restricted cash and cash equivalents (VIE)
1,489

 
8,143

 
47,762

 
1,803

Prepaid expenses and other current assets
625

 
606

 

 

Cash, cash equivalents and restricted cash per statement of cash flows
$
1,667,526

 
$
2,487,051

 
$
1,231,707

 
$
1,386,769

Schedule of new accounting pronouncements and changes in accounting principles
The cumulative effect of applying ASC 606 to the Company’s contracts with customers that were not completed as of January 1, 2018 was as follows:
 
Balance as of
 
 
 
Balance as of
 
December 31, 2017
 
Adjustments
 
January 1, 2018
Assets
(in thousands)
Accounts receivable, net
$
281,343

 
$
29,881

 
$
311,224

Inventories
111,830

 
(90
)
 
111,740

Prepaid expenses and other current assets
165,635

 
(17,166
)
 
148,469

Total assets
$
3,546,014

 
$
12,625

 
$
3,558,639

Liabilities and Shareholders’ Equity
 
 
 
 


Accrued expenses
$
443,961

 
$
8,586

 
$
452,547

Early access sales accrual
232,401

 
(7,273
)
 
225,128

Other liabilities, current portion
34,373

 
2,083

 
36,456

Accumulated other comprehensive loss
(11,572
)
 
949

 
(10,623
)
Accumulated deficit
(5,119,723
)
 
8,280

 
(5,111,443
)
Total liabilities and shareholders’ equity
$
3,546,014

 
$
12,625

 
$
3,558,639

The impact of adoption on the Company’s condensed consolidated balance sheet as of September 30, 2018 was as follows:
 
As of September 30, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
Assets
(in thousands)
Accounts receivable, net
$
379,755

 
$
345,180

 
$
34,575

Inventories
124,150

 
124,245

 
(95
)
Prepaid expenses and other current assets
118,678

 
143,826

 
(25,148
)
Total assets
$
4,620,840

 
$
4,611,508

 
$
9,332

Liabilities and Shareholders’ Equity
 
 


 


Accrued expenses
$
504,240

 
$
515,880

 
$
(11,640
)
Early access sales accrual
324,251

 
342,136

 
(17,885
)
Other liabilities, current portion
60,357

 
38,950

 
21,407

Accumulated other comprehensive income
307

 
186

 
121

Accumulated deficit
(4,540,005
)
 
(4,557,334
)
 
17,329

Total liabilities and shareholders’ equity
$
4,620,840

 
$
4,611,508

 
$
9,332

The impact of adoption on the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2018 was as follows:
 
Three Months Ended September 30, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
 
(in thousands)
Product revenues, net
$
782,511

 
$
777,117

 
$
5,394

Cost of sales
111,255

 
109,533

 
1,722

Income from operations
205,649

 
201,977

 
3,672

Net income attributable to Vertex
$
128,746

 
$
125,074

 
$
3,672

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
0.51

 
$
0.49

 
$
0.02

Diluted
$
0.50

 
$
0.48

 
$
0.02

 
Nine Months Ended September 30, 2018
 
As Reported
under ASC 606
 
Balances
without Adoption of ASC 606
 
Effect of Change
Higher/(Lower)
 
(in thousands)
Product revenues, net
$
2,170,152

 
$
2,156,156

 
$
13,996

Cost of sales
287,250

 
282,303

 
4,947

Income from operations
507,428

 
498,379

 
9,049

Net income attributable to Vertex
$
546,369

 
$
537,320

 
$
9,049

 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
Net income:
 
 
 
 
 
Basic
$
2.15

 
$
2.11

 
$
0.04

Diluted
$
2.11

 
$
2.07

 
$
0.04